Pharmacogenomics Market by Technology (Microarray, Polymerase Chain Reaction, Sequencing, Electrophoresis, Mass Spectrometry, and Others), Application (Infectious Diseases, Oncology, Neurological Diseases, Cardiovascular Diseases, Pain Management, Psychiatry, and Others), and End User (Research Institutions, Hospitals and Clinics, and Academic Institutes)-Global Industry Analytics, COVID-19 Business Impact, and Trends, 2020 - 2029

                                          
Abstract
                    
According to the report, global demand for pharmacogenomics market was valued at approximately USD 5,712.5 million in 2018, and is expected to generate revenue of around USD 10,492.2 million by end of 2025, growing at a CAGR of around 9.2% between 2019 and 2025.

The report covers forecast and analysis for the pharmacogenomics market on a global and regional level. The study provides historic data from 2016 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the pharmacogenomics market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the pharmacogenomics market on a global as well as regional level.

In order to give the users of this report a comprehensive view on the pharmacogenomics market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein Technology and services segment is benchmarked based on their market size, growth rate and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the pharmacogenomics market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new Technology launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the pharmacogenomics market on global and regional basis.

Pharmacogenomics is the combination of pharmacology and genomics. Pharmacogenomics studies the effect of genes on drug response. The aim of pharmacogenomics is to develop safe and effective doses and medication tailored to the genetic makeup of a person.

Factors such as increasing implementation of pharmacogenomics procedure, growing geriatric population, increasing adoption of personalized therapy, rapidly rising incidence of chronic disorders, and growing rate of adverse reactions will act as major driving factors in the growth of global pharmacogenomics market. Technological advancements in the field of pharmacogenomics and increasing awareness will act as an opportunity for the market players in the pharmacogenomics market. Nonetheless, high cost of diagnosis, lack of skilled professionals, and low awareness in developing regions will restrict the growth of global pharmacogenomics market.

The global pharmacogenomics market has been split into technology, application, end user, and region. Based on technology, pharmacogenomics market has been segmented into microarray, polymerase chain reaction, sequencing, electrophoresis, mass spectrometry, and others. The polymerase chain reaction segment accounted for the highest market share in 2018 due to irreplaceable nature. The application segment has been divided into infectious diseases, oncology, neurological diseases, cardiovascular diseases, pain management, psychiatry, and others. The end user segment has been divided into research institutions, hospitals and clinics, and academic institutes. The hospitals and clinics segment accounted for the highest market share in 2018 due to presence of latest molecular diagnostic infrastructure in hospitals.

North America will be the leading region during the forecast period. U.S. accounted for the highest share in the North America region due to growing execution of pharmacogenomics and quick implementation of latest healthcare technologies. Europe is likely to be the succeeding key market. The crucial reasons are existence of skilled healthcare professionals and increasing acceptance of personalized medicine. Asia Pacific will develop at the highest growth rate owing to presence of large patient group, rise in consciousness regarding pharmacogenomics, and high incidence of chronic diseases. Latin America region will propagate at a noteworthy rate through the assessment time. Middle East & Africa will show positive advancement in the projected time-frame.

The report also includes detailed profiles of key players such as Dynamic DNA Laboratories, Abbott Laboratories, Empire Genomics, LLC, Illumina, Inc., F. Hoffmann-La Roche Ltd., Myriad Genetics Inc., OneOme LLC, Thermo Fisher Scientific, Inc., and OPKO Health, Inc. among others.

This report segments the Global Pharmacogenomics Market as follows:

Global Pharmacogenomics Market: By Technology

	Microarray
	Polymerase Chain Reaction
	Sequencing
	Electrophoresis
	Mass Spectrometry
	Others

Global Pharmacogenomics Market: By Application

	Infectious Diseases
	Oncology
	Neurological Diseases
	Cardiovascular Diseases
	Pain Management
	Psychiatry
	Others

Global Pharmacogenomics Market: By End User

	Research Institutions
	Hospitals and Clinics
	Academic Institutes

Global Pharmacogenomics Market: By Region

	North America
	
		U.S.
	
	
	Europe
	
		UK
		France
		Germany
	
	
	Asia Pacific
	
		China
		Japan
		India
	
	
	Latin America
	
		Brazil
	
	
	Middle East and Africa